Technology Transfer Office

Transforming Our Discoveries Into Therapeutics

 

The Technology Transfer Office embodies the spirit of the National Jewish Health brand promise, Science Transforming Life®. We accelerate the development of basic scientific research towards clinical application by identifying and protecting the institution's intellectual property and facilitating business partnerships for technology development, licensing, and commercialization.

National Jewish Health currently has in its portfolio:

• 181 active technologies developed from our research
• 53 active US patents protecting these technologies
• 50 percent of those active US patents are licensed to biotechnology companies for the development of therapeutics consistent with the spirit of the National Jewish Health brand promise, Science Transforming Life®.

Additionally, in the 12 years since the Technology Transfer Office was created, National Jewish Health has:

• executed 195 license agreements, of which 114 are still active;
• executed a total of 1570 material transfer agreements; and
• helped create 8 start-up companies.

 

Technologies from National Jewish Health

To browse a list of the technologies ready for licensing or further development, select one of the following:

• Biotechnologies: By Type and Application or by Title
• Research Tools: Antibodies, Cell Lines,  Animal Models & Transgenic Mice
• Biomedical Devices
• Start Up Companies created with National Jewish Health technologies

 

Featured Technology:  Cystatin C: An Extracellular Antagonist of the TGF-ß Receptor. Potential Therapies for Cancer and Fibrotic Diseases

 

Staff

Emmanuel Hilaire, PhD Manager Phone: 303-398-1262 HilaireE@atopicderm.org

Stephanie Piersma Program Administrator Phone: 303-398-1045 [email protected]

Contact Information
National Jewish Health
Technology Transfer Office
1400 Jackson St., M206
Denver, CO 80206
Fax: 303-270-2352